Page 2 - Initial Results News Today

TEL AVIV, Israel & ZURICH & NEW YORK, September 11, 2023--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that initial results from trials conducted by the Mayo Clinic (as part of a previously announced collaboration) and by Imperial College London will be featured in two upcoming presentations at the Imperial Vulnerable Plaque and Patient...

31.07.2023 - LIMA, Peru, July 31, 2023 (GLOBE NEWSWIRE) - Minera IRL Limited (“Minera”, the “Company” or “we”) (BVL:MIRL) (CSE:MIRL) (FWB:DZX) (OTCQB:MRLLF) is pleased to report assay results from the final set of drill holes completed as part of Phase 1 of ...

Minera IRL Limited is pleased to report assay results from the final set of drill holes completed as part of Phase 1 of the Two-Phase Long-Hole Drilling Campaign currently underway at the...

Open access notables Back in April of 2020 Chi Xu et al. captivated some public attention with their paper Future of the human climate niche,  which explained a reasonable case for its startling conclusion about routine habitability of large parts of our planet now supporting dense populations. Now come the same researchers along with added talent to refine and extend those results, and the news isnt getting better. Quantifying the human cost of global warming paints a grim p...

- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival... | May 3, 2023

CFG INVESTMENT S.A.C. ANNOUNCES EXPIRATION AND FINAL RESULTS OF ITS EXTENDED OFFERS NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE...

You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and notes thereto for the... | March 27, 2023

01.03.2023 - - Achieved $31.3 Million in Net Revenue from Sales of COSELA (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - - Announced Top Line Results from Pivotal Phase 3 ...

No, a Dec. 1 study led by FDA researchers does not show that the Pfizer vaccines are linked to blood clotting, medical experts said.

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...